Core Viewpoint - Tianyuan Medical (00557) plans to acquire a 70% stake in Ningxia Deshang Outpatient Department Co., Ltd. for RMB 2.1 million, enhancing its presence in the Chinese medical service sector [1] Group 1: Acquisition Details - The acquisition involves Tianyuan Medical's indirect wholly-owned subsidiary, Zhongning Lekang Medical Technology Co., Ltd. [1] - The target company is established to conduct physical examination services in China [1] - The acquisition price is set at RMB 2.1 million [1] Group 2: Operational Insights - The target company's physical examination center has an operational area of approximately 3,869 square meters and employs 44 staff members, including 6 senior physicians [1] - The center is expected to continue generating revenue primarily from providing physical examination services in China [1] Group 3: Strategic Alignment - The acquisition aligns with the company's strategy to expand its medical services in China and strengthen its existing business in the medical sector [1] - The company aims to leverage the target's regional advantages and business foundation for resource integration and synergy [1] - The board believes that the acquisition will create synergistic effects and provide solid momentum for future growth [1]

Core Viewpoint - Tianyuan Medical (00557) is acquiring a 70% stake in Ningxia Deshang Outpatient Department Co., Ltd. for RMB 2.1 million, aiming to enhance its presence in the medical services sector in China [1] Group 1: Acquisition Details - The acquisition involves Tianyuan Medical's indirect wholly-owned subsidiary, Zhongning Lekang Medical Technology Co., Ltd. [1] - The target company is established to conduct physical examination services in China [1] - The expected area of operation for the target company's examination center is approximately 3,869 square meters, employing 44 staff members, including 6 senior physicians [1] Group 2: Strategic Implications - The acquisition aligns with the company's strategy to expand its medical services in China [1] - It is seen as an opportunity to strengthen existing operations in the medical business segment [1] - The company anticipates that the acquisition will create synergies and support ongoing growth in the Chinese medical market [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 須予披露交易－ 收購目標公司70%股權 交割須待股權轉讓協議中訂明的若干先決條件達成後，方可作實。概不保證任 何該等條件將會達成。因此，收購事項未必會進行。股東及潛在投資者於買賣 本公司證券時務請審慎行事。 緒言 董事會欣然宣佈，於二零二五年十二月三十一日（聯交所交易時段後），買方（本 公司之間接全資附屬公司）與賣方一及賣方二訂立股權轉讓協議，據此，買方有 條件同意收購而賣方有條件同意出售目標股權，代價為人民幣2,100,000元（相等 於約2,331,000港元）。交接及交割須待（其中包括）股權轉讓協議所載先決條件滿 足或獲豁免（倘適用）後，方可作實。 股權轉讓協議 股權轉讓協議之主要條款概述如下： 董事會欣然宣佈，於二零二五年十二月三十一 ...

Core Viewpoint - Tianyuan Medical (00557) announced that Tianyuan Manganese informed the company about an internal equity restructuring, where Ningxia Tianyuan Group will transfer 100% of its shares in Tianyuan Manganese to Ningxia Tianyuan Co., Ltd. This restructuring was completed on December 17, 2025 [1] Group 1 - Prior to the restructuring, Tianyuan Manganese directly held approximately 66.69% of the total issued shares of the company [1] - After the restructuring, Tianyuan Manganese is directly held 100% by Ningxia Tianyuan Co., Ltd., while Ningxia Tianyuan Co., Ltd. is directly held 100% by Ningxia Tianyuan Group [1] - The ultimate controlling shareholder remains Mr. Jia, who holds approximately 99.99% of Ningxia Tianyuan Group [1] Group 2 - The board of directors believes that the restructuring will not have any significant impact on the management and operations of the company [1]

Core Viewpoint - Tianyuan Medical (00557) announced that Tianyuan Manganese informed the company about an internal equity restructuring scheduled for December 17, 2025, involving a share transfer agreement between Ningxia Tianyuan Group and Ningxia Tianyuan Co., which will result in the transfer of 100% equity of Tianyuan Manganese to Ningxia Tianyuan Co. [1] Group 1 - The restructuring was completed on the same day it was announced, December 17, 2025 [1] - Prior to the restructuring, Tianyuan Manganese directly held approximately 66.69% of the total issued shares of the company [1] - Tianyuan Manganese was wholly owned by Ningxia Tianyuan Group, which is directly held by Mr. Jia, who owns approximately 99.99% [1] Group 2 - After the restructuring, Tianyuan Manganese is directly held 100% by Ningxia Tianyuan Co., while Ningxia Tianyuan Co. remains wholly owned by Ningxia Tianyuan Group, which is also directly held by Mr. Jia [1] - Tianyuan Manganese continues to hold approximately 66.69% of the total issued shares of the company [1] - The board believes that the restructuring will not have any significant impact on the management and operations of the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 自願公佈 控股股東股權架構變動 本公佈由本公司自願作出。 重組 本公司獲天元錳業告知，於二零二五年十二月十七日，由於天元錳業內部股權 重組，寧夏天元集團與寧夏天元股份訂立一份股權劃轉協議，據此，寧夏天元集 團將其持有的天元錳業100%股權無償劃轉予寧夏天元股份（「該重組」）。本公司 進一步獲告知，該重組已於同日（即二零二五年十二月十七日）完成。 收購守則之涵義 由於寧夏天元股份於該重組完成後間接收購本公司已發行股份總數約66.69%， 寧夏天元股份已申請，且執行人員已授出豁免，據此，根據收購守則第26.1條註 釋6(a)，寧夏天元股份無需因該重組而就本公司所有已發行股份提出全面要約。 釋義 於本公佈內，除文義另有所指外，下列詞彙具有以下涵義： ...

Group 1: Optical Communication Sector - The optical communication concept is experiencing a strong rebound, with companies like LIGONG Optical Science (300557) hitting the daily limit up of "20cm" [2] - Tongding Interconnection has seen a rise with two consecutive trading days of gains, while other companies such as Changfei Optical Fiber, Fenghuo Communication, and Hengtong Optic-Electric are also following suit [2] Group 2: Market Performance - The A-share market is showing overall positive performance, with all three major indices rising and a total market turnover of 12,860 billion, with over 4,600 stocks increasing in value [8] - The dairy industry concept is also gaining strength, with companies like Huanlejia reaching a "20cm" limit up and an increase of over 18% at the time of reporting [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/註冊股本總額： HKD 2,720,615,042 FF301 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2 ...